Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. - sprookjes - yvandenbroek - TriplyDB

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

http://www.wikidata.org/entity/Q35157985

about

Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR Erythropoietin and diabetes mellitus Stem cell guidance through the mechanistic target of rapamycin Erythropoietin: new directions for the nervous system Cutting through the complexities of mTOR for the treatment of stroke Targeting disease through novel pathways of apoptosis and autophagy Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin New Insights for Oxidative Stress and Diabetes Mellitus AMPK activation--protean potential for boosting healthspan.Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection Impairment of autophagy in the central nervous system during lipopolysaccharide-induced inflammatory stress in mice Rapamycin treatment improves neuron viability in an in vitro model of stroke.Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.Translating cell survival and cell longevity into treatment strategies with SIRT1 Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL SIRT1: new avenues of discovery for disorders of oxidative stress Deconvoluting mTOR biology Plant TOR signaling components Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL.Cardiovascular disease and mTOR signaling Mammalian target of rapamycin signaling in diabetic cardiovascular disease PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice Rapamycin protects neurons from brain contusion‑induced inflammatory reaction via modulation of microglial activation Regeneration in the nervous system with erythropoietin A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia.Novel directions for diabetes mellitus drug discovery mTOR: on target for novel therapeutic strategies in the nervous system.A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.Rapamycin, Autophagy, and Alzheimer's Disease Aging, neurogenesis, and caloric restriction in different model organisms.4EBP-Dependent Signaling Supports West Nile Virus Growth and Protein Expression.Involvement of interleukin-1β in the autophagic process of microglia: relevance to Alzheimer's disease Mammalian target of rapamycin (mTOR) pathways in neurological diseases.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.

P2860

Q26749047-792EFA56-8776-41E1-9F49-2E3077383208 Q26777878-639F2FD6-0A2B-4D9F-B935-6BC54A8D1B92 Q26795544-7E091F2F-90B4-42D5-B82D-2057C7D37A24 Q26828425-EAC2AFA1-C728-4FA8-9B06-B582C7C54B2A Q26851291-61C3C9DD-A9E2-4DBA-ACAA-5DE1A914B4B2 Q26864639-464A0B07-8410-4184-9C83-8F119A83AFE2 Q27015640-7E89CE7B-6574-4367-9AFD-50F7BFD5BD4B Q28080679-24F6D5E4-4FBF-48BE-B9CA-62B71987B10F Q33689169-0CA84CC8-AE2C-42E4-ADB9-04AC2B6655F0 Q34133074-281D04BD-945E-45CE-882F-8D385821ACB4 Q34429082-843E5282-7F38-4949-9886-7CE072A93A16 Q34545252-302BF6E7-B487-46DE-A494-FF914695A697 Q34827113-D3DAA833-C087-4753-A9CD-028FED7F006F Q35146283-81E6988C-6A0B-4552-AE18-97B04FC84B9E Q35278772-48275223-2765-4B67-891B-90543E3CE06E Q35660308-15DEB0DF-ABF2-4BC3-A29A-B538176DA85E Q35663684-A42B6F9E-D8CA-41FA-9687-2DB98B1CC4FE Q35742785-C2DB8F60-102C-447C-91BD-4BE98EBE838E Q35757288-D14F0E83-253C-49EA-B89B-47691EEA8940 Q35801388-6BEE87A9-184B-4A5D-8075-B957279E1C11 Q35896929-537D7D08-B541-4F80-9CD4-75FA30C70152 Q35947388-7C4A01B3-D322-4C74-805B-C54D03CEEEB4 Q36062316-56F59B21-DCAA-45FD-9002-191EEDCF6D03 Q36100715-E60A481A-2792-4F64-AE34-B5F56361107C Q36218704-4192C0A3-FA12-49FB-8464-3BD697E6E6D5 Q36224840-78236300-A292-43FD-963A-A1E93ACE0EBD Q36247651-E1367C94-C1F3-4F5C-BDB2-C8052BE03389 Q36379761-F16E6B3B-E7D7-4CB4-B1C0-B99F9164C125 Q36432388-307E46EA-C638-4574-8ECD-22FA1BE75555 Q36465550-CBE88005-2DA7-438E-99CE-3F8598BD9C14 Q36487424-3001909C-6D71-4FC8-B715-CBEA80FCCE13 Q36501214-4224A605-E50D-436A-835A-1BDFB086A731 Q36640327-90F1416B-C220-408D-87B1-CCB626ACFD3C Q36971857-3FCCA767-6FB8-4CF7-81D3-E6E96F3655E2 Q37070571-8407F715-582B-4958-B71A-E656F717F541 Q37378827-C9B879F6-4C0F-4123-BAB3-CA78F2C24907 Q37427068-8B4C22CB-6E65-4E13-929E-71E46127A0DE Q37432305-44358DDD-52B8-466E-B181-ABCD8C1E64AD Q37559812-E9F53872-AF4C-4CB9-BF6C-F360DF3411E7 Q37648017-DB9728AC-7506-4DEA-AE90-BA888A3028FA

P2860

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

http://www.wikidata.org/entity/Q35157985

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@ast

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@en

type

label

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@ast

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@en

prefLabel

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@ast

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@en

P1433

Q35157985-915E7761-BCB5-4F60-A3E5-FB288BEA1B45

P1476

Q35157985-EA76A5AC-75FF-4D06-B42B-DF3C33EF8D75

P2093

Q35157985-373AB759-EC64-4F1E-ACAC-6C5B17BDA794

Q35157985-55FC9618-F33D-4FEC-B22B-7687AE7A0E3D

Q35157985-80927010-2625-4FAC-9B37-8ECE0805B7A0

Q35157985-DCD30D88-E3EC-45EB-B7F0-F4D1985B1C12

Q35157985-EE91A6C9-EB9E-40B0-9398-1BCD2B638CC1

P2860

Q35157985-025B02CD-7E27-44E9-8A44-7E2353356DC7

Q35157985-03B9C699-7DA4-4DE0-8C38-1A07B7E35B37

Q35157985-0581BF0B-E0F4-42F5-93A8-19F042FEAA63

Q35157985-08218649-783B-4456-AF8E-214CF4983154

Q35157985-08635FF8-2E72-43C2-AF83-8A9BDFE6D859

Q35157985-0A58EEFF-E0BC-474D-975F-3A67D5CDA803

Q35157985-0A7452C3-CE47-4C87-BC87-2EB77E8B3CDE

Q35157985-0A7DD3DA-FC22-40D5-A66C-DC8440BDFDF1

Q35157985-0B969FDF-91D2-4980-80D6-6A8071C40E61

Q35157985-0D78A7FC-C199-4E62-96EB-8A92410961BB

P304

Q35157985-A257ADE1-A792-4004-B3B5-7CECD8FB0C94

P31

Q35157985-84687058-CED2-4A5C-A463-2961274612CE

Q35157985-F8E5AF9A-E115-41EE-A64F-13E7BA7E2F5F

P356

Q35157985-346DB7E8-C4DE-4B82-8497-33F57907FE2A

P433

Q35157985-7F3062EC-C595-44A5-9FE8-AB83D43332BA

P478

Q35157985-8F952DC9-5484-49D7-A7E3-23743647D82C

P577

Q35157985-F41F0A03-75DC-45A9-BDE5-5C1BF4C7D672

P5875

Q35157985-FA03C5BA-08FD-41A0-9DD7-D775703F54F0

P698

Q35157985-D57B4088-1744-428B-8E37-B45D418669EA

P921

Q35157985-21733C21-2CC3-41A7-841D-ED5F10F6F437

Q35157985-85DDDE93-FC57-4CBE-B0FC-2507054B988C

P932

Q35157985-9462503E-8ADF-4FEF-83E1-077DCBF47687

P356

P1433

Oxidative medicine and cellular longevity

P1476

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

@en

P2093

Kenneth Maiese

http://www.w3.org/2001/XMLSchema#string

Lijie Zhang

http://www.w3.org/2001/XMLSchema#string

Shaohui Wang

http://www.w3.org/2001/XMLSchema#string

Yan Chen Shang

http://www.w3.org/2001/XMLSchema#string

Zhao Zhong Chong

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease

Glucose-induced autophagy of peroxisomes in Pichia pastoris requires a unique E1-like protein

Induction of a cell stress response gene RTP801 by DNA damaging agent methyl methanesulfate through CCAA/enhancer binding protein

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

P304

374-391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/OXIM.3.6.14787

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49823394

http://www.w3.org/2001/XMLSchema#string

P698

21307646

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

3154047

http://www.w3.org/2001/XMLSchema#string